Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 169

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 169
---
endments), and to sign any registration statement for the same offering covered by this registration statement that is to be effective
upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933, and all post-effective amendments thereto, and
to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do
in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement on Form F-1 has been signed by the following persons in the capacities and on the
date indicated.

| Name and Signature        
 /s/ Stephen Stamp         |     | Title(s)                                                                                  
 Chief Executive Officer, Director,                                                        |     | Date              
 November 17, 2025 |
|:--------------------------|:----|:------------------------------------------------------------------------------------------|:----|:------------------|
| Stephen Stamp             |     | Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer |     |                   |
| /s/ Stephen Parker        |     | Non-Executive Chairman of the Board                                                       |     | November 17, 2025 |
| Stephen Parker            |     |                                                                                           |     |                   |
| /s/ Simon Turton, Ph.D.   |     | Senior Independent Non-Executive Director                                                 |     | November 17, 2025 |
| Simon Turton, Ph.D.       |     |                                                                                           |     |                   |
| /s/ Sijmen de Vries, M.D. |     | Non-Executive Director                                                                    |     | November 17, 2025 |
| Sijmen de Vries, M.D.     |     |                                                                                           |     |                   |
| /s/ Ann Merchant          |     | Non-Executive Director                                                                    |     | November 17, 2025 |
| Ann Merchant              |     |                                                                                           |     |                   |

| II-5 |

<div align='center'>AUTHORIZED REPRESENTATIVE</